Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
243
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Danielle S. Wallacea Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9371-6777View further author information
ORCID Icon,
Chris Rowlandb TG Therapeutics, Inc, New York, NY, USAView further author information
,
Brian T. Hillc Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAView further author information
,
Andrea M. Barand Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USAView further author information
,
Carla Casuloa Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Patrick M. Reagana Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Allison Winterc Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAORCID Iconhttps://orcid.org/0000-0002-8437-7539View further author information
ORCID Icon,
Reem Karmalie Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
,
Jane N. Wintere Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
,
Leo I. Gordone Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
,
Andrew Buib TG Therapeutics, Inc, New York, NY, USAView further author information
,
Peter Sportellib TG Therapeutics, Inc, New York, NY, USAView further author information
,
Hari P. Miskinb TG Therapeutics, Inc, New York, NY, USAView further author information
,
Michael S. Weissb TG Therapeutics, Inc, New York, NY, USAView further author information
,
Jonathan W. Friedberga Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Shuo Mae Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
&
Paul M. Barra Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
 show all
Pages 1579-1582 | Received 29 Apr 2023, Accepted 02 Jun 2023, Published online: 21 Jun 2023

References

  • Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386(26):2482–2494. doi: 10.1056/NEJMoa2201817.
  • Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard First-Line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022;140(Supplement 1):1–3. doi: 10.1182/blood-2022-163018.
  • Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563. doi: 10.1182/blood-2015-10-673145.
  • Zhao X, Lwin T, Silva A, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8(1):14920. doi: 10.1038/ncomms14920.
  • Ye H, Huang S, Jung D, et al. Simultaneous inhibition of BCL-2 and PI3K signaling overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2018;132(Supplement 1):2950–2950. doi: 10.1182/blood-2018-99-117013.
  • Portell CA, Wages NA, Kahl BS, et al. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(5):1490–1498. doi: 10.1182/bloodadvances.2021005357.
  • Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137(7):877–887. doi: 10.1182/blood.2020008727.
  • Barr PM, Hill BT, Ma S, et al. A phase 1/2 study of umbralisib ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):360–360. doi: 10.1182/blood-2019-123404.
  • Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019;134(21):1811–1820. doi: 10.1182/blood.2019002118.
  • Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833. doi: 10.1200/JCO.2016.70.4320.
  • Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol. doi: 10.1111/bjh.18519.
  • Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71. doi: 10.3324/haematol.2018.198812.
  • Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–567. doi: 10.1200/JCO.21.02370.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.